Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 1206-1209, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (23)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stenman, U.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stenman, U.-H.
Related Collections
Right arrow Cancer Diagnostics (since 2002)
(Clinical Chemistry. 2002;48:1206-1209.)
© 2002 American Association for Clinical Chemistry, Inc.

Reviews

Tumor-associated Trypsin Inhibitor

Ulf-Håkan Stenman1

1 Department of Clinical Chemistry, Helsinki University Central Hospital, Biomedicum, PB 700, FIN-00029 HUS, Finland.

Tumor-associated trypsin inhibitor (TATI) is a low-molecular-weight (6 kDa) trypsin inhibitor that has been used as a marker for ovarian cancer. It is also expressed together with tumor-associated trypsin by many other tumors, and increased serum concentrations of TATI occur in connection with these. TATI is a prognostic marker for ovarian, bladder, and kidney cancer, which may be associated with the participation of trypsin in protease cascades contributing to tumor invasiveness.




The following articles in journals at HighWire Press have cited this article:


Home page
 Mol Cancer ResHome page
N. Ozaki, M. Ohmuraya, M. Hirota, S. Ida, J. Wang, H. Takamori, S. Higashiyama, H. Baba, and K.-i. Yamamura
Serine Protease Inhibitor Kazal Type 1 Promotes Proliferation of Pancreatic Cancer Cells through the Epidermal Growth Factor Receptor
Mol. Cancer Res., September 1, 2009; 7(9): 1572 - 1581.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
G. Huang, Z. Hu, M. Li, Y. Cui, Y. Li, L. Guo, W. Jiang, and S. H. Lu
ECRG2 inhibits cancer cell migration, invasion and metastasis through the down-regulation of uPA/plasmin activity
Carcinogenesis, November 1, 2007; 28(11): 2274 - 2281.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
L. Valmu, A. Paju, M. Lempinen, E. Kemppainen, and U.-H. Stenman
Application of Proteomic Technology in Identifying Pancreatic Secretory Trypsin Inhibitor Variants in Urine of Patients with Pancreatitis
Clin. Chem., January 1, 2006; 52(1): 73 - 81.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
S. Malatos, H. Neubert, A. T. Kicman, and R. K. Iles
Identification of Placental Transforming Growth Factor-{beta} and Bikunin Metabolites as Contaminants of Pharmaceutical Human Chorionic Gonadotrophin Preparations by Proteomic Techniques
Mol. Cell. Proteomics, July 1, 2005; 4(7): 984 - 992.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. A. Rogers, P. Clarke, J. Noble, N. P. Munro, A. Paul, P. J. Selby, and R. E. Banks
Proteomic Profiling of Urinary Proteins in Renal Cancer by Surface Enhanced Laser Desorption Ionization and Neural-Network Analysis: Identification of Key Issues Affecting Potential Clinical Utility
Cancer Res., October 15, 2003; 63(20): 6971 - 6983.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Mandelin, H. Lassus, M. Seppala, A. Leminen, J.-A. Gustafsson, G. Cheng, R. Butzow, and R. Koistinen
Glycodelin in Ovarian Serous Carcinoma: Association with Differentiation and Survival
Cancer Res., October 1, 2003; 63(19): 6258 - 6264.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.